Market Research Logo

Global Oncology Drugs Market 2018-2024

Global Oncology Drugs Market 2018-2024

Global Oncology Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Oncology drugs or anti-cancer drugs or anti-neoplastic drugs are agents that can be used alone or in combination to control or destroy neoplastic cells. These agents can be either systemic or targeted. In systemic, the drug spreads throughout the body, whereas in targeted, the drug or substance identifies the specific location causing less harm to the growth of neighboring healthy cells. The oncology drugs market, by applications, is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. The incidence of cancer is one of the leading causes of death globally due to unhealthy food habits, changing lifestyle, and increasing consumption of tobacco-related products. According to the estimation of the National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people died due to cancer in 2016. Nearly 60% of new cancer cases are from Africa, Asia, Central and South American countries and almost 70% of cancer deaths are from these regions. The Indian Council for Medical Research estimated around 1.4 million new cancer cases in 2016, which is expected to rise to 1.7 million cases by 2020.
Increased prevalence of cancer, unhealthy lifestyle, and increasing geriatric population are the primary factors driving the market growth. However, the high cost of the drug & development process and side effects of the drug are the factors hampering the market growth. The development of pipeline oncology products and expiry of key patents are providing an opportunity for the manufacturers of cancer drugs.
Market Analysis: The global oncology drugs market is estimated to witness a CAGR of 7.0% during the forecast period 2018–2024. The market is analyzed based on three segments: therapeutic modality, applications, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the oncology drugs market growth followed by Europe, Asia Pacific, and Rest of the World.
Therapeutic Modality Analysis: The global oncology drugs market by therapeutic modality is segmented into chemotherapy, immunotherapy, targeted therapy, and others. Chemotherapy occupied the largest share in 2017, and immunotherapy is expected to grow at a high CAGR in the coming years due to high efficiency, increased preference of targeted immunotherapy from chemotherapy, and fewer side effects.
Applications Analysis: The global oncology drugs market by applications is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. Blood cancer occupied the largest share in 2017, and lung cancer application is expected to be the fastest growing segment during the forecast period due to the high incidence of lung cancer and promising pipeline for NSCLC drugs.
Key Players: F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Johnson & Johnson, Pfizer, Inc., Celgene Corporation, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Merck & Co., AbbVie, Inc., Sanofi, and other predominate & niche players.
Competitive Analysis: The high adoption of personalized medicine and immuno-oncology have fueled a shift in cancer treatment from chemotherapy in the past decade. During 2011–2017, around 84 new drugs have been approved across 22 indications globally, of which immuno-oncology PD-1 and PD-L1 inhibitors have seen a speedy uptake based on their notable clinical profile and approval for various cancers. Additionally, there is a robust late-stage oncology pipeline with around 630 unique molecules in the development, i.e., more than 7% when compared to the previous year, including 278 biological therapies and 82 vaccines. The market is dominated by key vendors such as F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Celgene Corporation, Pfizer Inc., and Johnson & Johnson; and products of these firms are available globally through their distributors and subsidiaries.
Benefits: The report provides complete details about the usage and adoption of oncology drugs in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:


1 INDUSTRY OUTLOOK 9
1.1 Industry overview 9
1.2 Industry Trends 9
1.3 Total addressable market 10
1.4 Trends of cancer therapy market 11
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 12
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Market Definition – Infoholic Research 14
3.2 Segmented Addressable Market (SAM) 14
3.3 Trends of the oncology drugs market 15
3.4 Related Markets 16
3.4.1 Over the counter drugs (OTC) 16
3.4.2 Active pharmaceutical ingredients (APIs) 17
3.4.3 Diabetes Drugs 17
4 Market Outlook 18
4.1 Oncology Drugs Approved by FDA (2014 – 2018) 18
4.2 Market segmentation 22
4.3 PEST Analysis 23
4.4 Porter 5(Five) Forces 24
5 Market Characteristics 25
5.1 DRO – Global Oncology Drugs Market Dynamics 25
5.1.1 Drivers 25
5.1.1.1 Increasing incidence of cancer across the globe 25
5.1.1.2 Growing geriatric population 26
5.1.1.3 Expiration of patents 26
5.1.2 Opportunities 27
5.1.2.1 Growing focus on personalized medicine 27
5.1.2.2 Increasing healthcare spending 27
5.1.3 Restraints 28
5.1.3.1 High cost of the drug 28
5.1.3.2 Side effects of oncology drugs 28
6 Therapeutic modality: Market Size and Analysis 31
6.1 Overview 31
6.2 Chemotherapy 32
6.3 Targeted therapy 33
6.4 Immunotherapy 34
6.5 Others 35
7 Application: Market Size and Analysis 37
7.1 Overview 37
7.2 Blood cancer 37
7.3 Breast cancer 38
7.4 Gastro intestinal cancer 39
7.5 Lung cancer 39
7.6 Prostate cancer 40
7.7 Others 40
8 Regions: Market Size and Analysis 41
8.1 Overview 41
8.2 North America 42
8.2.1 Overview 42
8.2.2 US 43
8.2.3 Canada 44
8.3 Europe 44
8.3.1 Overview 44
8.3.2 UK 45
8.3.3 Germany 46
8.3.4 France 46
8.3.5 Italy 46
8.4 APAC 47
8.4.1 Overview 47
8.4.2 India 48
8.4.3 China 48
8.5 Rest of the World 49
9 Competitive Landscape 50
9.1 Overview 50
10 Vendor Profiles 53
10.1 F.Hoffmann-La Roche Ltd 53
10.1.1 Overview 53
10.1.2 Business Unit 56
10.1.3 Geographic Presence 57
10.1.4 58
10.1.5 Business Focus 58
10.1.6 SWOT Analysis 58
10.1.7 Business Strategy 59
10.2 Novartis AG 60
10.2.1 Overview 60
10.2.2 Business Unit 63
10.2.3 Geographic Presence 63
10.2.4 Business Focus 64
10.2.5 SWOT Analysis 64
10.2.6 Business Strategy 65
10.3 Bristol-Myers Squibb 66
10.3.1 Overview 66
10.3.2 Geographic Presence 70
10.3.3 Business Focus 71
10.3.4 SWOT Analysis 71
10.3.5 Business Strategy 72
10.4 Celgene Corporation 73
10.4.1 Overview 73
10.4.2 Geographic Presence 75
10.4.3 Business Focus 75
10.4.4 SWOT Analysis 75
10.4.5 Business Strategy 76
10.5 Johnson & Johnson 77
10.5.1 Overview 77
10.5.2 Business Units 80
10.5.3 Geographic Revenue 81
10.5.4 Business Focus 82
10.5.5 SWOT Analysis 83
10.5.6 Business Strategies 83
10.6 Pfizer Inc., 84
10.6.1 Overview 84
10.6.2 Geographic Presence 87
10.6.3 Business Focus 88
10.6.4 SWOT Analysis 89
10.6.5 Business Strategies 89
11 Companies to Watch For 90
11.1 Astra Zenca PLC 90
11.1.1 Overview 90
11.2 Eli Lilly and Company. 91
11.2.1 Overview 91
11.3 GlaxoSmithKline plc 92
11.3.1 Overview 92
11.4 Merck & Co. 94
11.4.1 Overview 94
11.5 Sanofi 95
11.5.1 Overview 95
11.6 Amgen Inc. 96
11.6.1 Overview 96
11.7 AbbVie, Inc. 98
11.7.1 Overview 98
12 Annexure 100
12.1 Abbreviations 100
Tables
TABLE 1 GLOBAL ONCOLOGY DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($BILLION) 42
TABLE 1 GLOBAL ONCOLOGY DRUGS MARKET BY VENDOR RANKING, 2017 52
TABLE 2 OTHER PROMINENT VENDORS OF ONCOLOGY DRUGS MARKET 53
TABLE 3 F. HOFFMANN-LA ROCHE: OFFERINGS 54
TABLE 4 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 54
TABLE 5 NOVARTIS AG: OFFERINGS 60
TABLE 6 NOVARTIS AG: RECENT DEVELOPMENTS 61
TABLE 7 BRISTOL-MYERS SQUIBB: OFFERINGS 66
TABLE 8 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 67
TABLE 9 CELGENE CORPORATION: OFFERINGS 73
TABLE 10 CELGENE CORPORATION: RECENT DEVELOPMENTS 73
TABLE 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS 77
TABLE 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 78
TABLE 13 PFIZER, INC.: PRODUCT OFFERINGS 84
TABLE 14 PFIZER INC.: RECENT DEVELOPMENTS 85
TABLE 15 ASTRA ZENECA PLC.: SNAPSHOT 90
TABLE 16 ASTRA ZENECA PLC: RECENT DEVELOPMENTS 90
TABLE 17 ELI LILLY AND COMPANY: SNAPSHOT 91
TABLE 18 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 91
TABLE 19 GLAXOSMITHKLINE PLC.: OVERVIEW 92
TABLE 20 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 93
TABLE 21 MERCK & CO: OVERVIEW 94
TABLE 22 MERCK & CO: RECENT DEVELOPMENTS 94
TABLE 23 SANOFI: SNAPSHOT 95
TABLE 24 SANOFI: RECENT DEVELOPMENTS 96
TABLE 25 AMGEN INC.: SNAPSHOT 97
TABLE 26 AMGEN INC: RECENT DEVELOPMENTS 97
TABLE 27 ABBVIE INC: SNAPSHOT 98
TABLE 28 ABBVIE INC: RECENT DEVELOPMENTS 99
Charts
CHART 1 RESEARCH METHODOLOGY OF GLOBAL ONCOLOGY DRUGS MARKET
CHART 2 GLOBAL ONCOLOGY DRUGS MARKET REVENUE, 2017–2024 ($BILLION)
CHART 3 NUMBER OF ONCOLOGY DRUGS APPROVED FROM 2014-2017
CHART 4 SEGMENTATION OF GLOBAL ONCOLOGY DRUGS MARKET
CHART 5 PEST ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET
CHART 6 PORTER 5 FORCES ON GLOBAL ONCOLOGY DRUGS MARKET
CHART 7 DRO – IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET
CHART 8 KEY STAKEHOLDERS
CHART 9 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2017 (%)
CHART 10 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2024 (%)
CHART 11 GLOBAL CHEMOTHERAPY MARKET FORECAST, 2017–2024 ($BILLION)
CHART 12 GLOBAL TARGETED THERAPY MARKET FORECAST, 2017–2024 ($BILLION)
CHART 13 GLOBAL IMMUNOTHERAPY MARKET FORECAST, 2017–2024 ($BILLION)
CHART 14 GLOBAL OTHERS MARKET FORECAST, 2017–2024 ($BILLION)
CHART 15 GLOBAL ONCOLOGY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
CHART 16 GLOBAL ONCOLOGY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
CHART 17 ONCOLOGY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($BILLION)
CHART 18 ONCOLOGY DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($BILLION)
CHART 19 ONCOLOGY DRUGS REVENUE IN ASIA-PACIFIC, 2017–2024 ($BILLION)
CHART 20 ONCOLOGY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($BILLION)
CHART 25 NOVARTIS AG: OVERVIEW SNAPSHOT
CHART 26 NOVARTIS AG: BUSINESS UNITS
CHART 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE
CHART 28 NOVARTIS AG: SWOT ANALYSIS
CHART 29 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT
CHART 30 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS
CHART 31 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE
CHART 32 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS
CHART 33 CELGENE CORPORATION: OVERVIEW SNAPSHOT
CHART 34 CELGENE CORPORATION: GEOGRAPHIC PRESENCE
CHART 35 CELGENE CORPORATION: SWOT ANALYSIS
CHART 36 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 37 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 38 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
CHART 39 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 40 PFIZER INC.,: OVERVIEW SNAPSHOT
CHART 41 PFIZER INC.: BUSINESS UNITS REVENUE
CHART 42 PFIZER INC.: GEOGRAPHICAL PRESENCE
CHART 43 PFIZER INC.: SWOT ANALYSIS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report